Amlodipine and Valsartan Tablets, USP 10/320 mg, 30-count bottles, Rx Only, Made in India, Manufa...
FDA Drug Recall #D-0323-2019 — Class II — December 4, 2018
Recall Summary
| Recall Number | D-0323-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 4, 2018 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mylan Laboratories Limited, (Nashik FDF) |
| Location | Sinnar, Nashik District, N/A |
| Product Type | Drugs |
| Quantity | 84,066 HDPE bottles |
Product Description
Amlodipine and Valsartan Tablets, USP 10/320 mg, 30-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., NDC 0378-1724-93.
Reason for Recall
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Distribution Pattern
Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Lot / Code Information
Lot Numbers: 3066064, 3069645, 3069646, 3073142, 3073143, 3073144, 3077617
Other Recalls from Mylan Laboratories Limited, (Nashik FDF)
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0322-2019 | Class II | Amlodipine and Valsartan Tablets, USP 5/320 mg,... | Dec 4, 2018 |
| D-0328-2019 | Class II | Valsartan and Hydrochlorothiazide Tablets, USP ... | Dec 4, 2018 |
| D-0320-2019 | Class II | Amlodipine and Valsartan Tablets, USP 5/160 mg... | Dec 4, 2018 |
| D-0326-2019 | Class II | Valsartan Tablets, USP 160 mg, 90-count bottles... | Dec 4, 2018 |
| D-0331-2019 | Class II | Valsartan and Hydrochlorothiazide Tablets, USP ... | Dec 4, 2018 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.